Neurogen Will Advance Insomnia Drug Based On Positive Top-Line Phase IIb Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Improved specificity will make NG2-73 first-line therapy of choice for the vast majority of insomnia sufferers, Neurogen R&D chief says.